– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 March 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last ...
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it raised capital in the U.S. to accelerate clinical development and business development activities for the Company’s lead asset, ATH434. Based ...
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Today at 11:00 a.m. ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 January 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, has released a Shareholder Newsletter. You can access the full newsletter in this link: https://mailchi.mp/we-worldwide/alterity-therapeutics-shareholder-newsletter-january-2025 Below is an excerpt of the newsletter, a ...
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative ...
Good morning, everyone, and thank you for joining us today here in Melbourne. It is my pleasure to share with you my Chairman’s address for Alterity Therapeutics Fiscal Year 2024 Annual General Meeting. This has been a year of significant progress and achievement for Alterity, marked by important milestones in our mission to develop disease-modifying ...
AGM 2024 Presentation
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International ...
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 6 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the ...
